Literature DB >> 9353121

The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1.

A Matilla1, B T Koshy, C J Cummings, T Isobe, H T Orr, H Y Zoghbi.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder characterized by ataxia, progressive motor deterioration, and loss of cerebellar Purkinje cells. SCA1 belongs to a growing group of neurodegenerative disorders caused by expansion of CAG repeats, which encode glutamine. Although the proteins containing these repeats are widely expressed, the neurodegeneration in SCA1 and other polyglutamine diseases selectively involves a few neuronal subtypes. The mechanism(s) underlying this neuronal specificity is unknown. Here we show that the cerebellar leucine-rich acidic nuclear protein (LANP) interacts with ataxin-1, the SCA1 gene product. LANP is expressed predominantly in Purkinje cells, the primary site of pathology in SCA1. The interaction between LANP and ataxin-1 is significantly stronger when the number of glutamines is increased. Immunofluorescence studies demonstrate that both LANP and ataxin-1 colocalize in nuclear matrix-associated subnuclear structures. The features of the interaction between ataxin-1 and LANP, their spatial and temporal patterns of expression, and the colocalization studies indicate that cerebellar LANP is involved in the pathogenesis of SCA1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353121     DOI: 10.1038/40159

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  56 in total

1.  Aggregation of truncated GST-HD exon 1 fusion proteins containing normal range and expanded glutamine repeats.

Authors:  B Hollenbach; E Scherzinger; K Schweiger; R Lurz; H Lehrach; E E Wanker
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.

Authors:  A S Hackam; J G Hodgson; R Singaraja; T Zhang; L Gan; C A Gutekunst; S M Hersch; M R Hayden
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

3.  Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Authors:  P H Reddy; V Charles; M Williams; G Miller; W O Whetsell; D A Tagle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

4.  Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin.

Authors:  S H Li; A L Cheng; H Li; X J Li
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

Review 5.  The complex clinical and genetic classification of inherited ataxias. I. Dominant ataxias.

Authors:  S Di Donato
Journal:  Ital J Neurol Sci       Date:  1998-12

Review 6.  Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts?

Authors:  D C Rubinsztein; A Wyttenbach; J Rankin
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

7.  Cracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.

Authors:  Patrick T Reilly; Yun Yu; Ali Hamiche; Lishun Wang
Journal:  Bioessays       Date:  2014-08-25       Impact factor: 4.345

Review 8.  Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies.

Authors:  Alexander G Yakovlev; Alan I Faden
Journal:  NeuroRx       Date:  2004-01

Review 9.  Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold.

Authors:  H L Paulson
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

10.  Cpd-1 null mice display a subtle neurological phenotype.

Authors:  Rupinder K Kular; Rocky G Gogliotti; Puneet Opal
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.